XRF SCIENTIFIC LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.44 AUD | -0.69% |
|
+13.83% | +22.03% |
| 16/04 | XRF Scientific's Profit Before Tax Rises 15% in March Quarter | MT |
| 20/02 | XRF Scientific Shares Decline 5% Despite Higher Fiscal H1 Revenue, EPS | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- With an enterprise value anticipated at 3.2 times the sales for the current fiscal year, the company turns out to be overvalued.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
Ratings chart - Surperformance
Sector: Office Equipment
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +22.03% | 131M | - | ||
| +18.23% | 26.57B | A- | ||
| +26.18% | 5.18B | B | ||
| +24.51% | 4.56B | B+ | ||
| +27.18% | 1.64B | A- | ||
| -14.21% | 1.11B | - | ||
| +8.87% | 1.07B | - | - | |
| -36.58% | 895M | - | ||
| -5.68% | 737M | B | ||
| +3.54% | 449M | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- XRF Stock
- Ratings XRF Scientific Limited
